Jaume Alijotas Reig Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca Email Jaume Alijotas Reig Email Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca
Research lines Endothelial senescence and their pleiotropic effects onto inflamatory processes, inmunological response and angiogenesis. Identification at the molecular level of pathways and proteins associated with the senescence of endothelial cells linked to aging and inflamatory responses. New candidate targets for therapeutic intervention at the clinical level and as new molecular moieties for nanomedicine approaches to improve aging related pathologies caused by endothelial inflamatory based senescence. IP: Jaume Alijotas Reig Immunologic lesional mechanisms in late adverse reactions against bioimplants. The late clinical manifestations that arise when bioimplants are applied seem to have an immunologic basis. We are studying both the histological characteristics and the lesional mechanisms of the most frequently used implants. We try to analyze the role that bacteria may have in the induction and/or maintenance of these reactions and the possible correlation between particular HLA haplotypes and the adverse effects. IP: Jaume Alijotas Reig Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Projects Envejecimiento endotelial y sus efectos pleiotrópicos sobre procesos inflamatorios, de la respuesta inmune y angiogénesis IP: Francesc Miro Mur Collaborators: Jaume Alijotas Reig, Simon Schwartz Navarro Funding agency: Fundación Invest. Médica Mutua Madrileña Funding: 36000 Reference: FMMA/05/2008 Duration: 24/09/2008 - 23/09/2011 CIBER: Bioingenieria, biomateriales y nanomedicina IP: - Collaborators: CIBER: Bioingenieria, biomateriales y nanomedicina, Manuel López Cano, Jaume Alijotas Reig, Francesc Miro Mur, Eloy Espín Basany, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina Funding agency: CIBER Bioing., Biomateriales y Nanomedicina , BBN Funding: 480000 Reference: CB06/01/0012 Duration: 01/01/2007 - 31/12/2010 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3
